GH Research (NASDAQ:GHRS) Trading 3.1% Higher – Time to Buy?

GH Research PLC (NASDAQ:GHRS)’s stock price traded up 3.1% on Monday . The stock traded as high as $9.05 and last traded at $8.88. 18,510 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 79,195 shares. The stock had previously closed at $8.61.

Analyst Ratings Changes

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.

GH Research Stock Performance

The business’s 50 day moving average price is $7.72 and its 200-day moving average price is $10.40.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Research analysts forecast that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its holdings in GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the period. GH Research makes up approximately 9.1% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 6th largest position. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).